1-6 of 6
Blanca Homet
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma

Aude Fléchon, Rafael Morales-Barrera, Thomas Powles, Ajjai Alva, Mustafa Özgüroğlu, Tibor Csöszi, Yohann Loriot, Alejo Rodriguez-Vida, Lajos Géczi, Susanna Y. Cheng, Yves Fradet, Stéphane Oudard, Christof Vulsteke, Seyda Gunduz, Ronac Mamtani, Evan Y. Yu, Alvaro Montesa Pino, Urbano Anido, Mehmet A.N. Sendur, Gwenaelle Gravis, János Révész, Vladimir Kostorov, Olivier Huillard, Junshui Ma, Mohini Rajasagi, Amir Vajdi, Jared Lunceford, Razvan Cristescu, Kentaro Imai, Blanca Homet Moreno, Nobuaki Matsubara
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (23): 5353–5364.
https://doi.org/10.1158/1078-0432.CCR-23-3518
Published: 02 December 2024
View article titled, Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma
Open the PDF for Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma in another window
Includes: Supplementary data
Journal Articles

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2050–2060.
https://doi.org/10.1158/1078-0432.CCR-21-3089
Published: 13 May 2022
View article titled, Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Open the PDF for Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials in another window
Includes: Supplementary data
Journal Articles

Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules

Georgina V. Long, Caroline Robert, Marcus O. Butler, Felix Couture, Matteo S. Carlino, Steven O'Day, Victoria Atkinson, Jonathan S. Cebon, Michael P. Brown, Stéphane Dalle, Andrew G. Hill, Geoffrey T. Gibney, Steven McCune, Alexander M. Menzies, Cuizhen Niu, Nageatte Ibrahim, Blanca Homet Moreno, Adi Diab
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5280–5288.
https://doi.org/10.1158/1078-0432.CCR-21-0793
Published: 01 October 2021
View article titled, Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Open the PDF for Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules in another window
Includes: Supplementary data
Journal Articles

Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B

Matteo S. Carlino, Alexander M. Menzies, Victoria Atkinson, Jonathan S. Cebon, Michael B. Jameson, Bernard M. Fitzharris, Catriona M. McNeil, Andrew G. Hill, Antoni Ribas, Michael B. Atkins, John A. Thompson, Wen-Jen Hwu, F. Stephen Hodi, Alexander D. Guminski, Richard Kefford, Haiyan Wu, Nageatte Ibrahim, Blanca Homet Moreno, Georgina V. Long
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (19): 5086–5091.
https://doi.org/10.1158/1078-0432.CCR-20-0177
Published: 01 October 2020
View article titled, Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
Open the PDF for Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B in another window
Includes: Supplementary data
Journal Articles

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study

Michael B. Atkins, F. Stephen Hodi, John A. Thompson, David F. McDermott, Wen-Jen Hwu, Donald P. Lawrence, Nancy A. Dawson, Deborah J. Wong, Shailender Bhatia, Marihella James, Lokesh Jain, Seth Robey, Xinxin Shu, Blanca Homet Moreno, Rodolfo F. Perini, Toni K. Choueiri, Antoni Ribas
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (8): 1805–1815.
https://doi.org/10.1158/1078-0432.CCR-17-3436
Published: 12 April 2018
View article titled, Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
Open the PDF for Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study in another window
Includes: Supplementary data
Journal Articles

CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire

Lidia Robert, Jennifer Tsoi, Xiaoyan Wang, Ryan Emerson, Blanca Homet, Thinle Chodon, Stephen Mok, Rong Rong Huang, Alistair J. Cochran, Begoña Comin-Anduix, Richard C. Koya, Thomas G. Graeber, Harlan Robins, Antoni Ribas
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (9): 2424–2432.
https://doi.org/10.1158/1078-0432.CCR-13-2648
Published: 30 April 2014
View article titled, CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
Open the PDF for CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire in another window
Includes: Supplementary data